It is our pleasure to announce the 11th Neurodegenerative Diseases Research & Development Conference, to be held September 11-12, 2017 in Boston, MA. The drug discovery effort for neurodegenerative diseases has been one of the major challenges of the pharmaceutical industry. This conference will connect scientists and researchers to share perspectives on the latest topics of interest, such as targeted treatments for psychiatric disorders, neuroinflammation, and cell- and gene-therapy based therapies.
This program strives to go beyond just dialogue around research itself, but the partnerships and alliances that need to be formed in order to continue pushing research forward into the future. What are the best models of private/public partnerships? How are patient advocacy groups changing the way we think about funding and research? Colleagues will have the opportunity to build new relationships and move forward together towards the future of neuroscience.
We hope you’ll join us in Boston for a productive and informative meeting!
Joint Plenary Sessions:
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Round Table Discussions: Neuroinflammation, Neuroimaging & Translational Biomarkers
III. Ready, Set, Grow – New Company/Technology Pitch Competition
IV. Award Ceremony & Closing Keynote Session – Predictions for future
11th Neurodegenerative Diseases Research & Development
I. Experimental Therapeutics & Approaches in Alzheimer’s Disease & Related Dementias
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Next Frontier in Multiple Sclerosis to Limit or Reverse Neurodegeneration
IV. Therapeutics for Rare & Orphan CNS Disorders
The 2017 Advisory Committee
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
SRI provides broad expertise in antiviral and vaccine efficacy /safety studies, utilizing its extensive collection of human and animal Influenza isolates, and providing: in vitro evaluation, customizable in vivo models, vaccine discovery /development, discovery tools in ferret model. SRI offers research, discovery /development CRO services, Phase I Clinical Trials.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Renovo Neural Inc. is a specialized preclinical research organization offering services that revolutionize biological research and development of neural therapies. Renovo’s preclinical models for neurodegenerative diseases, customized neurohistology and automated electron microscopy services provide high-quality standard and customizable solutions for basic science, preclinical and clinical research. Renovo provides these specialized research services to pharmaceutical & biotechnology companies, research organizations and academic investigators.
Merck has worked for more than 150 years to discover, develop and deliver vaccines, medications and animal health products that save and improve millions of lives. Partnerships are a vital part of our strategy for bringing forward new therapies. Discover more about how we can work together at www.merck.com/licensing.